EIN 31-1621592

International Vaccine Institute (IVI)

IRS 501(c) type
Num. employees
Year formed
Most recent tax filings
The mission of International Vaccine Institute is to discover, develop, and deliver safe, effective and affordable vaccines for global public health.
Total revenues
Total expenses
Total assets
Num. employees

Program areas at IVI

The purpose of gbp510 phase iii clinical trial is to demonstrate that the immune response induced by 2 doses of gbp510 at 4-week interval in seronegative adults aged 18 years and older is superior /non-inferior to the immune response induced by 2 doses of chadox1-s (astrazeneca). In january 2022, almost 3500 participants were enrolled at the 22 study sites across 5 countries, thailand, philippines, vietnam, new zealand and ukraine. Throughout the year 2022, 8 participant visits were completed including 6 blood collections for data analysis. From q2 2022, stage 2 follow up study (immune response of third dose of gbp510) at 2 sites in thailand, started in parallel with the initial phase iii study. In q3 2022, gbp510, brand named skycovione has been authorized by the korean ministry of food and drug safety (kmfds).
In 2019, ivi began simplifying ocv through a reformulation of the Vaccine to lower the cost of production by 20% while increasing production capacity of euvichol by 35%. In october 2022, ivi completed the clinical trial comparing the lower-cost formulation (euvichol-s) to shanchol. A final study report is forthcoming in early 2023.
In the first half of 2022, the gccdp team completed quality audits for the study sites in costa rica and panama, and two quality control visits were performed by ivi study team. In june, the second data and safety monitoring board meeting was held and concluded with a "go" safety decision to initiate the phase iii component of the study. Follow-up monitoring of trial participants in phase ii (850 ppl) continued for 12 months and completed by november. No serious unexpected adverse reactions have been observed. The british national Institute for biological standards and control, gccdp's partner laboratory for the non-human primate (nhp) study, completed the active immunization study and the final report is now available. Study data demonstrated potent protection with bharat biotech's bbv87 chikungunya Vaccine by both the impact on virus replication and host response to infection. The interim clinical study report was finalized in july 2022, and unblinded immunogenicity results are now available. Together with the nhp study findings, these results supported the selection of the optimal dose for the phase iii. Meanwhile, ivi is working closely with the project's funder, cepi, and the who on Vaccine value profile development for chikungunya.
All other programs

Grants made by IVI

GranteeGrant descriptionAmount
International Vaccine Institute (IVI)Program Service$291,514
Professional Nurses Chapter of the Brigham and Women's HospitalProgram Service$143,231
Harvard UniversityProgram Service$56,928
...and 2 more grants made

Who funds International Vaccine Institute (IVI)

Grants from foundations and other nonprofits
Bill & Melinda Gates FoundationEmpower Women and Girls$5,000,000
Good Ventures FoundationClinical Trial of Vaccine Against Hepatitis E in Pregnant Women in Pakistan$3,000,000
Good Ventures FoundationClinical Trial of Conjugate Vaccine for Cholera$2,500,000
...and 12 more grants received

Personnel at IVI

Francois BelinDeputy Director General , Chief Operating Officer$446,807
Goan Yeoun Moon, M.B.A.Chief of Staff
Dr. Melanie SavilleExecutive Director, Vaccine Research and Development$0
Laura Plant, Ph.D.Head of External Affairs Europe Regional Office
Tae Kyung Byun, M.A.Head of Government and Public Relations
...and 21 more key personnel

Financials for IVI

RevenuesFYE 12/2022
Total grants, contributions, etc.$77,015,644
Program services$0
Investment income and dividends$486,502
Tax-exempt bond proceeds$0
Royalty revenue$0
Net rental income$0
Net gain from sale of non-inventory assets$0
Net income from fundraising events$0
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$-1,344,260
Total revenues$76,157,886

Form 990s for IVI

Fiscal year endingDate received by IRSFormPDF link
2022-122023-10-25990View PDF
2021-122022-11-08990View PDF
2020-122021-11-09990View PDF
2019-122021-02-24990View PDF
2018-122019-10-12990View PDF
...and 8 more Form 990s
Data update history
December 4, 2023
Posted financials
Added Form 990 for fiscal year 2022
December 3, 2023
Updated personnel
Identified 5 new personnel
November 27, 2023
Received grants
Identified 1 new grant, including a grant for $291,514 from International Vaccine Institute (IVI)
October 20, 2023
Updated personnel
Identified 10 new personnel
August 5, 2023
Posted financials
Added Form 990 for fiscal year 2021
Nonprofit Types
Social advocacy organizationsInternational-focused organizations
Foreign affairsPublic policy
Fundraising eventsOperates internationallyReceives government funding
General information
Snu Research Park 1 Gwanak-Ro
Korea, 00000
Website URL
Facebook page
Twitter profile
IRS details
Fiscal year end
Taxreturn type
Form 990
Year formed
Eligible to receive tax-deductible contributions (Pub 78)
NTEE code, primary
Q05: International, Foreign Affairs and National Security Research Institutes and Public Policy Analysis
NAICS code, primary
813319: Social Advocacy Organizations
Parent/child status
Free account sign-up

Want updates when IVI has new information, or want to find more organizations like International Vaccine Institute (IVI)?

Create free Cause IQ account